Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omission of 5-fluorouracil bolus vs oxaliplatin dose reduction in colorectal cancer
TCTR20190909001Phase 3Recruiting
- Sponsor
- -
- Start
- Jul 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in colorectal cancer (CRC) comparing Omission of bolus fluorouracil first with Oxaliplatin dose reduction first (2 arms). Primary endpoint: Rate of recurrent neutropenia. Started Jul 2019; status: recruiting.
02
Drugs
fluorouraciloxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on TCTR20190909001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190909001.